Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan-Mar;61(1):2-10.
doi: 10.22336/rjo.2017.2.

Matrix regenerative therapy

Cristina-Mihaela Timaru  1 , Cornel Stefan  1 , Daniela Adriana Iliescu  1 , Algerino De Simone  1 , Mehdi Batras  1
Affiliations
Review

Matrix regenerative therapy

Cristina-Mihaela Timaru et al. Rom J Ophthalmol. 2017 Jan-Mar.

Abstract

The extracellular matrix (ECM) is responsible for many of the cell behavior processes, including cell proliferation and growth, survival, change in cell shape, migration, and differentiation. The most important component of the ECM is heparan sulfate (HS), because it insures the storage of many cell communication proteins, necessary for the continuous and identical renewal of cells and thus for tissue regeneration. Regenerating agents (RGTA®) are bioengineered structural analogues of heparan sulfate glycosaminoglycans that replace the degraded endogenous HS of the ECM. In the ophthalmological field, RGTA® represents an innovative approach for the improvement of the ocular surface wound healing and matrix remodeling and plays a role in controlling and regulating the wound healing process in various ocular diseases.

Keywords: RGTA; extracellular matrix; regenerating agents; wound healing.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
47-year-old female patient, infectious corneal ulcer; 1 - day 1 of treatment, 2a,b - follow-up day 30, 3a,b - follow-up day 60
Fig. 2
Fig. 2
42-year-old male patient, linear corneal dystrophy; 1a,b - day 1 of treatment, 2a,b - follow-up day 30, 3 - follow-up day 90
Fig. 3
Fig. 3
57-year-old male patient, post corneal transplant; 1a,b - day 1 of treatment, 2 - follow-up 60 days
Fig. 4
Fig. 4
59-year-old male patient, post corneal transplant, 1a,b - day 1 of treatment, 2a,b - follow-up 90 days
Fig. 5
Fig. 5
39-year-old female patient, post refractive surgery, 1 - day 1 of treatment, 2 -follow-up 30 days
Fig. 6
Fig. 6
45-year-old female, severe dry eye syndrome, 1 - day 1 of treatment, 2 - follow-up 30 days, 3 - follow up 90 days, 4 - follow-up 120 days
Fig. 7
Fig. 7
40-year-old female patient, viral keratitis, 1a,b - first day of treatment, 2a,b - follow-up at 30 days, 3 - follow-up at 90 days
See this image and copyright information in PMC

References

    1. Bowling B. Kanski’s Clinical Ophthalmology. eight edition. 2016. pp. 168–169.
    1. Dua HS, Faraj LA, Said DG, Gray T, Lowe J. Human corneal anatomy redefined: a novel pre-Descemet’s layer (Dua’s layer) Ophthalmology. 120(9):1778–1785. doi:10.1016/j.ophtha.2013.01.018. - PubMed
    1. Badylak S. Regenerative medicine and developmental biology: The role of the extracellular matrix. The Anatomical Record. 2005 - PubMed
    1. Tsirogianni AK, Moutsopoulos NM, Moutsopoulos HM. Wound healing: immunological aspects. Injury. 2006 Apr;37(Suppl 1):S5–S12. - PubMed
    1. Liu CY, Kao WW. Corneal Epithelial Wound Healing. Prog Mol Biol Transl Sci. 2015;134:61–71. - PubMed

MeSH terms

Substances

LinkOut - more resources